A groundbreaking re-analysis of data from the large-scale AMARANTH clinical trial has been presented in a recent issue of Nature Communications. Initial tests of the drug lanabecestat, designed to reduce β-amyloid levels in the brain, were previously deemed unsuccessful as they failed to show significant cognitive improvements in participants.
However, an international team of scientists applied an advanced Artificial Intelligence (AI) tool, specifically a Predictive Prognostic Model (PPM), to the same original dataset. This innovative model is capable of analyzing various baseline patient indicators, including MRI data, genetic markers, β-amyloid levels, and memory test results, to accurately forecast the rate of Alzheimer`s disease progression in an individual. This unique approach enabled researchers to divide trial participants into two distinct groups: those experiencing “slow” and “rapid” neurodegeneration progression.
Following this new stratification, it was remarkably discovered that for patients exhibiting a slower disease progression, taking 50 milligrams of lanabecestat slowed cognitive decline by a significant 46 percent compared to the placebo group. Notably, no such beneficial effect was observed in patients with rapid disease progression. Furthermore, the successful application of AI demonstrated its potential to significantly reduce the required sample size for detecting a therapeutic effect in future studies, promising to accelerate and considerably reduce the costs of upcoming clinical trials.
Researchers emphatically highlight the immense potential of integrating artificial intelligence into the realm of clinical research. They believe this can substantially enhance the overall efficiency of trials and help to much more quickly discover effective treatments for complex and debilitating conditions like Alzheimer`s disease.
In related findings, scientists have also recently discovered that regular consumption of chicken eggs could significantly lower the risk of developing Alzheimer`s disease. Individuals who consumed at least two eggs per week reportedly had a 47 percent lower chance of developing dementia.
